Therapeutic Class

Bristol Myers taps cash rich Cellares for CAR-T processing

Therapeutic Class

Bristol Myers taps cash rich Cellares for CAR-T processing Bristol Myers taps cash rich Cellares for CAR-T processing

Having raised $255 million and laid ground on a third facility, cell therapy technology firm Cellares has inked a deal with Bristol Myers.

byDan Stanton, Editorial director

Aug 29, 2023

|

1 Min Read

Plant maintenance poses supply blips as BCMA CAR-T rivalry heats up

Therapeutic Class

Plant maintenance poses supply blips as BCMA CAR-T rivalry heats up Plant maintenance poses supply blips as BCMA CAR-T rivalry heats up

Aug 23, 2023

1 Min Read

Cytomos bags $5m to advance cell analysis platform

Therapeutic Class

Cytomos bags $5m to advance cell analysis platform Cytomos bags $5m to advance cell analysis platform

byMillie Nelson

Aug 14, 2023

1 Min Read

Kyverna CAR-T pipeline boosted by $145m funding

Therapeutic Class

Kyverna CAR-T pipeline boosted by $145m funding Kyverna CAR-T pipeline boosted by $145m funding

byMillie Nelson

Aug 8, 2023

1 Min Read

Oramed and Hefei Tianhui form $60m oral insulin JV

Therapeutic Class

Oramed and Hefei Tianhui form $60m oral insulin JV Oramed and Hefei Tianhui form $60m oral insulin JV

byRichard Daverman

Aug 7, 2023

1 Min Read

Kriya bags another $150m funding to explore gene therapies

Therapeutic Class

Kriya bags another $150m funding to explore gene therapies Kriya bags another $150m funding to explore gene therapies

byMillie Nelson

Aug 2, 2023

1 Min Read

Biogen Q2: Jobs slashed to save $1bn, plus biosimilar burdens

Therapeutic Class

Biogen Q2: Jobs slashed to save $1bn, plus biosimilar burdens

Biogen Q2: Jobs slashed to save $1bn, plus biosimilar burdens

byDan Stanton, Editorial director

Soaring CGT demand altering bioprocess pipelines

Therapeutic Class

Soaring CGT demand altering bioprocess pipelines

Soaring CGT demand altering bioprocess pipelines

byMillie Nelson, Editor

Sandoz to build $90m Slovenian biosimilars center

Therapeutic Class

Sandoz to build $90m Slovenian biosimilars center

Sandoz to build $90m Slovenian biosimilars center

byDan Stanton, Editorial director

WuXi Bio plans ADC spin-off and $500m Hong Kong IPO

Therapeutic Class

WuXi Bio plans ADC spin-off and $500m Hong Kong IPO

WuXi Bio plans ADC spin-off and $500m Hong Kong IPO

byRichard Daverman, Dan Stanton

Astraveus exits stealth mode with $18m to advance CGT platform

Therapeutic Class

Astraveus exits stealth mode with $18m to advance CGT platform

Astraveus exits stealth mode with $18m to advance CGT platform

byMillie Nelson, Editor

WestGene raises $42m in mRNA focused Series A funding

Therapeutic Class

WestGene raises $42m in mRNA focused Series A funding

WestGene raises $42m in mRNA focused Series A funding

byRichard Daverman

Ultragenyx: MA plant to support AAV gene therapy pipeline

Therapeutic Class

Ultragenyx: MA plant to support AAV gene therapy pipeline

Ultragenyx: MA plant to support AAV gene therapy pipeline

byDan Stanton, Editorial director

Bio testing demand being propelled by CGTs, says Charles River

Therapeutic Class

Bio testing demand being propelled by CGTs, says Charles River

Bio testing demand being propelled by CGTs, says Charles River

byDan Stanton, Editorial director

‘No surprises:’ AGC promising fixed timelines for mAbs and more

Therapeutic Class

‘No surprises:’ AGC promising fixed timelines for mAbs and more

‘No surprises:’ AGC promising fixed timelines for mAbs and more

byMillie Nelson, Editor

Flexibility key to keeping up with CGT’s changing tech needs, CBM

Therapeutic Class

Flexibility key to keeping up with CGT’s changing tech needs, CBM

Flexibility key to keeping up with CGT’s changing tech needs, CBM

byMillie Nelson, Editor

CGT CDMO roundup: News from CRL, NorthX, and Avirmax

Therapeutic Class

CGT CDMO roundup: News from CRL, NorthX, and Avirmax

CGT CDMO roundup: News from CRL, NorthX, and Avirmax

byMillie Nelson, Editor

Syncona launches 3rd gene therapy firm through $120m funding

Therapeutic Class

Syncona launches 3rd gene therapy firm through $120m funding

Syncona launches 3rd gene therapy firm through $120m funding

byMillie Nelson, Editor

BMS $30bn CAR-T vision boosted by MA plant approval

Therapeutic Class

BMS $30bn CAR-T vision boosted by MA plant approval

BMS $30bn CAR-T vision boosted by MA plant approval

byDan Stanton, Editorial director

Bayer licenses lipid nanoparticle tech for gene therapy

Therapeutic Class

Bayer licenses lipid nanoparticle tech for gene therapy

Bayer licenses lipid nanoparticle tech for gene therapy

J&J on CGTs: ‘We are disease, not modality-centric’

Therapeutic Class

J&J on CGTs: ‘We are disease, not modality-centric’

J&J on CGTs: ‘We are disease, not modality-centric’

byDan Stanton, Editorial director

What comes after mRNA? Self-amplified RNA, states industry report

Therapeutic Class

What comes after mRNA? Self-amplified RNA, states industry report

What comes after mRNA? Self-amplified RNA, states industry report

byMillie Nelson, Editor

ReNAgade takes off with $300m+ to tackle RNA challenges

Therapeutic Class

ReNAgade takes off with $300m+ to tackle RNA challenges

ReNAgade takes off with $300m+ to tackle RNA challenges

byMillie Nelson, Editor

Novartis adding cystinosis gene therapy candidate from AvroBio

Therapeutic Class

Novartis adding cystinosis gene therapy candidate from AvroBio

Novartis adding cystinosis gene therapy candidate from AvroBio

byDan Stanton, Editorial director

NewBiologix launches with $50m to develop CGT platform

Therapeutic Class

NewBiologix launches with $50m to develop CGT platform

NewBiologix launches with $50m to develop CGT platform

byMillie Nelson, Editor

Ascend launches with $130m to tackle manufacturability of AAVs

Therapeutic Class

Ascend launches with $130m to tackle manufacturability of AAVs

Ascend launches with $130m to tackle manufacturability of AAVs

byDan Stanton, Editorial director

IgE antibodies could be potential solid tumor treatments, says UCL

Therapeutic Class

IgE antibodies could be potential solid tumor treatments, says UCL

IgE antibodies could be potential solid tumor treatments, says UCL

byGareth Macdonald

The future of CGT production? Automation, AI, and academic capacity

Therapeutic Class

The future of CGT production? Automation, AI, and academic capacity

The future of CGT production? Automation, AI, and academic capacity

byDan Stanton, Editorial director

Tubulis deal sees Bristol bolster ADC commitment

Therapeutic Class

Tubulis deal sees Bristol bolster ADC commitment

Tubulis deal sees Bristol bolster ADC commitment

byDan Stanton, Editorial director

Pfizer touts mRNA as alternative to current flu vaccines

Therapeutic Class

Pfizer touts mRNA as alternative to current flu vaccines

Pfizer touts mRNA as alternative to current flu vaccines

CPhI NA: CGT big picture ‘strong’ despite investment slowdown

Therapeutic Class

CPhI NA: CGT big picture ‘strong’ despite investment slowdown

CPhI NA: CGT big picture ‘strong’ despite investment slowdown

byDan Stanton, Editorial director

UK Gov sets up £10m CGT manufacturing center

Therapeutic Class

UK Gov sets up £10m CGT manufacturing center

UK Gov sets up £10m CGT manufacturing center

byGareth Macdonald

Gracell closes cell therapy deal with Seagen

Therapeutic Class

Gracell closes cell therapy deal with Seagen

Gracell closes cell therapy deal with Seagen

byRichard Daverman

Regeneron probing bispecific Abs with eye on future cancer therapies

Therapeutic Class

Regeneron probing bispecific Abs with eye on future cancer therapies

Regeneron probing bispecific Abs with eye on future cancer therapies

byGareth Macdonald

Digitalized platform aims to help Bayer exceed in CGT space

Therapeutic Class

Digitalized platform aims to help Bayer exceed in CGT space

Digitalized platform aims to help Bayer exceed in CGT space

Subscribe to receive our monthly print or digital publication

Join our 70,000+ readers. And yes, it's completely free.